Study: NCT02440035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.FA2
Description: Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.